Effectiveness and Safety of Microwave Ablation Therapy in Parathyroid Adenomas

Furkan Ertürk Urfali; Bünyamin Aydin; Sezgin Zeren; Güven Barış Cansu; Mustafa Cem Algin; Mehmet Korkmaz

doi:10.1055/s-0043-1764436

The Arab Journal of Interventional Radiology, Table of Contents

CC BY 4.0 · The Arab Journal of Interventional Radiology 2023; 07(01): 039-043
DOI: 10.1055/s-0043-1764436

Original Article

Effectiveness and Safety of Microwave Ablation Therapy in Parathyroid Adenomas

Authors

Furkan Ertürk Urfali

¹Deparment of Interventional Radiology, Kutahya Health Science University, Istiklal, Kutahya, Turkey
Bünyamin Aydin

²Deparment of Endocrinology and Metabolic Diseases, Kutahya Health Science University, Istiklal, Kutahya, Turkey
Sezgin Zeren

³Deparment of General Surgery, Kutahya Health Science University, Istiklal, Kutahya, Turkey
Güven Barış Cansu

²Deparment of Endocrinology and Metabolic Diseases, Kutahya Health Science University, Istiklal, Kutahya, Turkey
Mustafa Cem Algin

³Deparment of General Surgery, Kutahya Health Science University, Istiklal, Kutahya, Turkey
Mehmet Korkmaz

¹Deparment of Interventional Radiology, Kutahya Health Science University, Istiklal, Kutahya, Turkey

Abstract

Objective We report the effectiveness and safety of ultrasound (US) guided microwave ablation (MWA) treatment of parathyroid adenomas.

Materials and Methods A total of 35 patients underwent US-guided MWA therapy of parathyroid adenomas. Before the procedure, blood parathyroid hormone (PTH; mean: 202.32 ± 158.46 ng/L) level, calcium (mean: 11.65 ± 0.53 mg/dL) level, and parathyroid adenoma volume (mean: 1.76 ± 0.73 cm³) were recorded. Blood parameters and US-guided follow-up evaluations were performed at 1 and 3 months after the procedure.

Results Technical success was 91% for the first session. There was a statistically significant decrease in parathyroid adenoma size and calcium and PTH levels at 3 months of follow-up (p < 0.001). A perfect positive correlation (r: 0.927; p < 0.001) was found between the ablation time and the adenoma size. Transient vocal cord paralysis occurred in two (5.7%) patients and short-term (<2 hours) local pain occurred in four (11.4%) patients after the procedure.

Conclusion US-guided MWA is effective in the treatment of parathyroid adenomas with low complication risk. Our preliminary results showed that MWA treatment resulted in an effective improvement in blood tests and adenoma size.

Keywords

ablation - parathyroid - ultrasound

Full Text

References

References
1 Liu F, Yu X, Liu Z. et al. Comparison of ultrasound-guided percutaneous microwave ablation and parathyroidectomy for primary hyperparathyroidism. Int J Hyperthermia 2019; 36 (01) 835-840
2 Erturk MS, Cekic B, Sarı IK, Pamuk BO. Microwave ablation as an efficient therapy for primary hyperparathyroidism: efficacy and predictors of treatment success. Int J Clin Pract 2021; 75 (10) e14580
3 Hamdy NA. Parathyroid gland: is parathyroidectomy safe and beneficial in the elderly?. Nat Rev Endocrinol 2009; 5 (08) 422-423
4 Bilezikian JP, Brandi ML, Eastell R. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99 (10) 3561-3569
5 Liu F, Zang L, Liu Y. et al. Risk factors influencing cure of ultrasound-guided microwave ablation for primary hyperparathyroidism. Int J Hyperthermia 2022; 39 (01) 258-264
6 Zhuo L, Peng LL, Zhang YM. et al. US-guided microwave ablation of hyperplastic parathyroid glands: safety and efficacy in patients with end-stage renal disease-a pilot study. Radiology 2017; 282 (02) 576-584
7 Wang G, Liu S, Liu X, Qian L, Diao Z, Liu W. Microwave ablation: an effective treatment for mild-to-moderate secondary hyperparathyroidism in patients undergoing haemodialysis. Int J Hyperthermia 2017; 33 (08) 946-952
8 Zhuo L, Zhang L, Peng LL. et al. Microwave ablation of hyperplastic parathyroid glands is a treatment option for end-stage renal disease patients ineligible for surgical resection. Int J Hyperthermia 2019; 36 (01) 29-35
9 Fan BQ, He XW, Chen HH, Zhang WM, Tang W. US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study. Eur Radiol 2019; 29 (10) 5607-5616
10 Liu C, Wu B, Huang P. et al. US-guided percutaneous microwave ablation for primary hyperparathyroidism with parathyroid nodules: feasibility and safety study. J Vasc Interv Radiol 2016; 27 (06) 867-875
11 Wahl DA, Cooper C, Ebeling PR. et al. A global representation of vitamin D status in healthy populations. Arch Osteoporos 2012; 7: 155-172
12 Rolighed L, Rejnmark L, Sikjaer T. et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 2014; 99 (03) 1072-1080
13 Ying W, Zhen-Long Z, Xiao-Jing C, Li-Li P, Yan L, Ming-An Y. A study on the causes of operative failures after microwave ablation for primary hyperparathyroidism. Eur Radiol 2021; 31 (09) 6522-6530
14 Baloch ZW, LiVolsi VA. Pathology of the parathyroid glands in hyperparathyroidism. Semin Diagn Pathol 2013; 30 (03) 165-177
15 Insogna KL. Primary hyperparathyroidism. N Engl J Med 2018; 379 (11) 1050-1059
16 Carsello CB, Yen TW, Wang TS. Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter?. Surgery 2012; 152 (04) 575-581 , discussion 581–583
17 Diao Z, Liu X, Qian L, Liu J, Liu S, Liu W. Efficacy and its predictor in microwave ablation for severe secondary hyperparathyroidism in patients undergoing haemodialysis. Int J Hyperthermia 2016; 32 (06) 614-62